Jean Jacques Bienaime - Apr 18, 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Apr 18, 2022
Transactions value $
-$889,000
Form type
4
Date filed
4/20/2022, 08:20 PM
Previous filing
Apr 18, 2022
Next filing
May 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $749K +20K +5.97% $37.46 355K Apr 18, 2022 Direct F1
transaction BMRN Common Stock Sale -$1.64M -20K -5.63% $81.91 335K Apr 18, 2022 Direct F1
holding BMRN Common Stock 248K Apr 18, 2022 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -20K -26.67% $0.00 55K Apr 18, 2022 Common Stock 20K $37.46 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 60% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.